Brief: Cabaletta Bio Receives Additional FDA Fast Track Designations For Caba-201 In Dermatomyositis And Systemic Sclerosis
08/01/2024 13:57
Jan 8 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO RECEIVES ADDITIONAL FDA FAST TRACK
DESIGNATIONS
FOR CABA-201 IN DERMATOMYOSITIS AND SYSTEMIC SCLEROSIS
Source text for Eikon: ID:nGNXbjBBlT
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity